NCT05877924View on ClinicalTrials.gov

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Malignant Tumors
Interventions
DRUG

NBL-020 for Injection

NBL-020 for Injection, Q3W, i.v.

Trial Locations (1)

Unknown

RECRUITING

Wu Yilong, Guanzhou

Sponsors
All Listed Sponsors
lead

NovaRock Biotherapeutics, Ltd

INDUSTRY

NCT05877924 - A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. | Biotech Hunter | Biotech Hunter